Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease
- PMID: 35764179
- DOI: 10.1016/j.addr.2022.114402
Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease
Abstract
Lysosomes have a critical role in maintaining normal cellular homeostasis mediated by their involvement in secretion, plasma membrane repair, cell signaling and energy metabolism. Lysosomal storage disorders (LSDs) are a group of approximately 50 rare disorders caused by lysosomal dysfunction that occur due to mutations in a gene of a lysosomal protein. Gaucher disease (GD), an autosomal recessive disorder and one of the most common LSDs, is caused by the deficiency of the lysosomal enzyme acid-β-glucocerebrosidase (GCase), due to biallelic mutations in the GBA1 gene. Reduced GCase activity leads to the accumulation of glucosylceramide (GlcCer), which is deacylated by lysosomal acid ceramidase to a toxic metabolite, glucosylshpingosine (GlcSph). Most GBA1 variants are recognized as misfolded in the ER, where the retention for refolding attempts initiates stress and activates the stress response known as the Unfolded Protein Response (UPR). The distinct clinical subtypes of GD are based on whether there is primary involvement of the central nervous system. Type 1 GD (GD1) is the nonneuropathic type, however, the recent recognition of the association of GD with the development of parkinsonism defies this classification. Patients with GD1 and carriers of GBA1 mutations are at risk for the development of parkinsonian manifestations. Parkinson disease (PD), the second most prevalent neurodegenerative disease, culminates in a movement disorder with the premature death of the patients. In PD and related disorders, collectively called synucleinopathies, the hallmark pathology is α-synuclein positive aggregates referred to as Lewy bodies or Lewy neurites and the death of dopaminergic neurons. While PD is mostly sporadic, in ∼5-10% of cases, the disease results from pathogenic variants in a growing number of genes. The most common genetic cause of PD is mutations in GBA1. Two mechanisms have been proposed for this link: (A) a "gain of function" mechanism, in which mutant GCase (protein) contributes to aggregate formation and to the development of PD, and the (B) "haploinsufficiency" ("loss of function") model, suggesting that one normal GBA1 allele is insufficient to carry adequate GCase activity and functional deficiency of GCase impedes α-synuclein metabolism. Lysosomal dysfunction, compromised autophagy and mitophagy further enhance the accumulation of α-synuclein, which results in the development of PD pathology. The present review will elaborate on the biology of GD, its association with PD and related disorders, and discuss the possible mechanisms underlying this association.
Keywords: Gaucher disease; Glucocerebrosidase (GCase); Misfolding; Parkinson disease; Unfolded Protein Response (UPR).
Copyright © 2022 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MH received grants from SHIRE Pharmaceuticals (now Takeda) and from Pfizer Pharmaceuticals Ltd. HB has no competing interests. AZ receives honoraria from Takeda, Pfizer and BioEvents and consultancy from Takeda, NLC Pharma, Prevail Therapeutics and InsighTec. SRV receives grant/research support, honoraria, and advisory fee from Takeda, Pfizer, and Sanofi/Genzyme. The Gaucher Unit at Shaare Zedek Medical Center receives support from Sanofi/Genzyme for participation in the ICGG Registry, from Takeda for the GOS Registry and from Pfizer for TALIAS. The Unit also receives research grants from Takeda, Pfizer, Sanofi/Genzyme, and Centogene. OGA received a grant support from Sanofi for the clinical trial NCT02906020 and is a consultant for Prevail therapeutics.
Similar articles
-
Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.Hum Mol Genet. 2023 May 18;32(11):1888-1900. doi: 10.1093/hmg/ddad025. Hum Mol Genet. 2023. PMID: 36752535 Free PMC article.
-
The relationship between glucocerebrosidase mutations and Parkinson disease.J Neurochem. 2016 Oct;139 Suppl 1(Suppl Suppl 1):77-90. doi: 10.1111/jnc.13385. Epub 2016 Feb 10. J Neurochem. 2016. PMID: 26860875 Free PMC article. Review.
-
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.Mol Genet Metab. 2020 Feb;129(2):35-46. doi: 10.1016/j.ymgme.2019.10.006. Epub 2019 Oct 23. Mol Genet Metab. 2020. PMID: 31761523 Free PMC article. Review.
-
Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.Hum Mol Genet. 2016 Aug 15;25(16):3432-3445. doi: 10.1093/hmg/ddw185. Epub 2016 Jul 4. Hum Mol Genet. 2016. PMID: 27378698 Free PMC article.
-
Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.Pharmacol Ther. 2023 Jun;246:108419. doi: 10.1016/j.pharmthera.2023.108419. Epub 2023 Apr 19. Pharmacol Ther. 2023. PMID: 37080432 Review.
Cited by
-
The Expression and Secretion Profile of TRAP5 Isoforms in Gaucher Disease.Cells. 2024 Apr 20;13(8):716. doi: 10.3390/cells13080716. Cells. 2024. PMID: 38667330 Free PMC article.
-
Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders.Adv Drug Deliv Rev. 2023 Jun;197:114683. doi: 10.1016/j.addr.2022.114683. Epub 2023 Jan 16. Adv Drug Deliv Rev. 2023. PMID: 36657645 Free PMC article. Review.
-
Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease.Hum Mol Genet. 2024 Aug 18;33(17):1467-1480. doi: 10.1093/hmg/ddae081. Hum Mol Genet. 2024. PMID: 38757200 Free PMC article.
-
Allosteric Modulation of GCase Enhances Lysosomal Activity and Reduces ER Stress in GCase-Related Disorders.Int J Mol Sci. 2025 May 6;26(9):4392. doi: 10.3390/ijms26094392. Int J Mol Sci. 2025. PMID: 40362629 Free PMC article.
-
Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.Hum Mol Genet. 2023 May 18;32(11):1888-1900. doi: 10.1093/hmg/ddad025. Hum Mol Genet. 2023. PMID: 36752535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical